Amneal Pharmaceuticals, Inc.
AMRX
$11.90
-$0.29-2.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.90M | 3.38M | -13.05M | -116.89M | -184.45M |
| Total Depreciation and Amortization | 240.48M | 245.36M | 240.82M | 236.19M | 226.99M |
| Total Amortization of Deferred Charges | 45.15M | 48.15M | 48.72M | 48.72M | 26.94M |
| Total Other Non-Cash Items | 206.60M | 131.06M | 128.89M | 131.15M | 215.58M |
| Change in Net Operating Assets | -170.37M | -76.87M | -98.47M | -4.07M | 27.78M |
| Cash from Operations | 327.76M | 351.08M | 306.92M | 295.10M | 312.84M |
| Capital Expenditure | -78.14M | -80.20M | -64.40M | -60.34M | -49.67M |
| Sale of Property, Plant, and Equipment | 1.38M | 1.38M | 524.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 7.01M | 7.01M | 11.99M | 11.99M | 4.99M |
| Other Investing Activities | -13.11M | -9.30M | -9.15M | -14.65M | -33.95M |
| Cash from Investing | -82.87M | -81.12M | -61.03M | -63.00M | -78.63M |
| Total Debt Issued | 2.92B | 218.00M | 218.00M | 48.00M | 374.73M |
| Total Debt Repaid | -2.86B | -393.82M | -405.27M | -233.12M | -440.15M |
| Issuance of Common Stock | 1.56M | 1.52M | 1.20M | 1.15M | 1.05M |
| Repurchase of Common Stock | -22.34M | -22.41M | -22.38M | -7.95M | -7.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -119.23M | -37.70M | -19.35M | -19.88M | -179.32M |
| Cash from Financing | -82.61M | -234.40M | -227.80M | -211.79M | -251.42M |
| Foreign Exchange rate Adjustments | -2.21M | -1.51M | -1.30M | -999.00K | -58.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 160.06M | 34.05M | 16.78M | 19.31M | -17.26M |